On Friday, CEO Dawn Svoronos bought 50,500 shares of her own company in the open market. She paid between $0.27 and $0.28 for the shares.
She was joined, a day earlier, by company insider Gérald Lacoste, who bought 40,000 shares at $0.27 and $0.275.
Theratechnologies’ management is no doubt hoping 2013 will be an improvement over a 2012 that was difficult for its investors. Shares of the company fell in half last June when Ferrer announced it would withdraw the marketing authorization application with the European Medicines Agency for Egrifta, the company’s tesamorelin application proposed for the treatment of excess abdominal fat in HIV patients with lipodystrophy.
Byron Capital healthcare analyst Douglas Loe thinks Theratechnologies will trade sideways until its regulatory status, which has been a persistent theme with the company, is resolved in Latin America and in Europe.
At press time, shares of Theratechnologies on the TSX were even at $0.285.
Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]
He feels the company made forward progress in its recent quarterly results, but Roth MKM analyst Rohit Kulkarni wants to… [Read More]
Following the company's first quarter results, Desjardins analyst Benoit Poirier has raised his price target on Bombardier (Bombardier Stock Quote,… [Read More]
With the integration of Shaw Communications underway, RBC analyst Drew McReynolds says Rogers Communications (Rogers Communications Stock Quote, Chart, News,… [Read More]
Following fourth quarter results he describes as "stronger than expected", Beacon Securities analyst Russell Stanley has raised his price target… [Read More]
Ahead if its first quarter results, Citi analyst Filippo Falorni says there is not much to like about Molson Coors… [Read More]